

# Chargeurs Buy

### Equity Research from Kepler Cheuvreux

Release date: 28 September 2022

### Baptiste de Leudeville

MCap: EUR268.9m

Equity Research Analyst +33 1 53 65 36 55 bdeleudeville@keplercheuvreux.com

### France | Support services

**Target Price:** EUR22.00 (30.00) Current Price: EUR11.40 Up/downside: 93.0% Market data: 27 September 2022

Change in TP: Change in Sales:

Change in Adj. EPS:

-26.7% -4.3% 22F/-6.1% 23F **Change in Adj. EBIT:** -22.8% 22E/-23.5% 23E -36.6% 22E/-43.2% 23E

Bloomberg: CRI FP Reuters: CRIP.PA Free float 73.0% Avg. daily volume (EURm) 0.9 -56.3% YTD abs performance 52-week high/low (EUR) 28.94/11.40

### **Estimates and TP cut, Buy maintained**

### Why this report?

Taken individually, core businesses were still developing well in the first half (resilient margin in protective films, profit recovery in fashion, active build-up in Museum Studio). Nevertheless, it did not stop the shares from plummeting further (-26% since publication, -56% YTD) on the back of darker economic prospects and the lack of short-term catalysts pending the recognition of profits from large museum projects and in the context of the deflation of the face-masks business. Some scepticism from investors about further recent diversification moves may be a factor too. We cut our TP from EUR30 to EUR22 and maintain our Buy rating.

### **Key findings**

- Fundamentals are intact. The investment case remains attractive (leadership in niche markets, premium positioning, state-of-the-art production assets, attractive outlook in museum services)...
- ...but the short-term outlook is undermined by a weaker macro environment and a lack of catalysts. We believe this is now reflected in the share price.

### **Deconstructing the forecasts**

■ The change in TP mostly reflects a new cut in revenue forecasts from face masks and, to a lesser extent, more prudence in protective films in a changing macroeconomic environment.

FY to 31/12 (EUR)	12/22E	12/23E	12/24E
Sales (m)	747.8	766.6	809.0
EBITDA adj (m)	65.7	71.8	81.1
EBIT adj (m)	43.5	49.5	57.8
Net profit adj (m)	22.2	24.0	31.0
Net financial debt (m)	148.4	144.0	135.2
FCF (m)	23.6	30.2	36.0
EPS adj. and ful. dil.	0.93	1.01	1.30
Consensus EPS	1.23	1.59	2.02
Net dividend	0.70	0.76	0.99
FY to 31/12	12/22E	12/23E	12/24E
FY to 31/12 P/E adj and ful. dil.	<b>12/22E</b> 12.3	<b>12/23E</b> 11.3	<b>12/24E</b> 8.8
P/E adj and ful. dil.	12.3	11.3	8.8
P/E adj and ful. dil. EV/EBITDA	12.3 6.9	11.3 6.3	8.8 5.5
P/E adj and ful. dil. EV/EBITDA EV/EBIT	12.3 6.9 10.5	11.3 6.3 9.1	8.8 5.5 7.6
P/E adj and ful. dil. EV/EBITDA EV/EBIT FCF yield	12.3 6.9 10.5 8.8%	11.3 6.3 9.1 11.2%	8.8 5.5 7.6 13.4%
P/E adj and ful. dil. EV/EBITDA EV/EBIT FCF yield Dividend yield	12.3 6.9 10.5 8.8% 6.2%	11.3 6.3 9.1 11.2% 6.7% 2.4	8.8 5.5 7.6 13.4% 8.7% 2.1
P/E adj and ful. dil. EV/EBITDA EV/EBIT FCF yield Dividend yield ND(F+IFRS16)/EBITDA	12.3 6.9 10.5 8.8% 6.2% 2.7	11.3 6.3 9.1 11.2% 6.7% 2.4 54.8%	8.8 5.5 7.6 13.4% 8.7% 2.1 49.3%

### **Investment case**

- Chargeurs is an industrial conglomerate with world-leading positions in niche markets that are worth EUR0.5-1.0bn (e.g. self-adhesive films for surface protection, interlinings and technical textiles, premium wool trading).
- CEO and reference shareholder Michael Fribourg took over the company in 2015 and reshaped it. The group's portfolio of assets has been strengthened (higher share of services, innovative/sustainable products, more productive industrial facility) making Chargeurs a more diversified, performing and premium business.

### **Catalysts**

- M&A (Museum Studio, personal care, luxury goods).
- Creation of the leading integrated player in services to
- Embedded performance of newly acquired assets and investments.

### **Valuation methodology**

■ Discounted cash flow (8.7% WACC, 2% g).

### Risks to our rating

- Deep economic recession.
- M&A execution.
- High price of raw materials (ex: polyethylene).

Kepler Cheuvreux and the issuer have agreed that Kepler Cheuvreux will produce and disseminate investment research on the said issuer as a service to the issuer.

### **Estimates and TP cuts**

We cut adjusted EBIT estimates by 23% on 2022 and 2023. The main change in estimates occurs in the Personal Care unit. The sales momentum in face masks since the beginning of the year (only EUR6m in Q1, no revenue in Q2) has prompted us to slash forecasts. It is reasonable to expect very limited profit from that business going forward with regards to global health and the company's strategy (no further investment, limited and stable number of customers).

In protective films, we have reviewed estimates moderately to reflect the risk of a weaker economic outlook in the year ahead, particularly in the construction sector (the main end market for protective films).

Our revenue estimates by 2025 (EUR861m) are below the long-term guidance (EUR1.0bn) set by the company before the pandemic. We do not think the company's financial targets are achievable in a deteriorated environment.


	Nev	w estimates		Old	l estimates		Change in estimates		
	2022E	2023E	2024E	2022E	2023E	2024E	2022E	2023E	2024E
Sales	748	767	809	781	816	855	-4%	-6%	-5%
EBITDA	66	72	81	80	89	98	-18%	-19%	-17%
EBIT, adj.	43	49	58	56	65	73	-23%	-23%	-21%
Net profit	22	24	31	31	34	41	-28%	-30%	-25%

For our valuation, we use a DCF with an implicit horizon to 2025 (matching the timeframe of the company's Leap Forward strategic plan). We obtain EUR22 (EUR30 previously) after cutting estimates. DCF assumptions from 2025 include 2% terminal growth and an EBIT margin of 6.7%. The sensitivity table below provides values ranging from EUR18 to EUR27.

An SOP valuation would be ideal to value a conglomerate like Chargeurs, but the company operates niche businesses where we lack relevant listed peers and transaction data. The lack of maturity of some businesses is also an obstacle.

				g		
		1.5%	1.8%	2.0%	2.3%	2.5%
	9.2%	18.4	19.2	20.1	21.0	21.9
	8.9%	19.3	20.1	21.0	22.0	23.1
WACC	8.7%	20.2	21.1	22.1	23.2	24.3
	8.4%	21.2	22.2	23.2	24.4	25.6
	8.2%	22.3	23.4	24.5	25.8	27.1

The shares are trading at rather low multiples compared to the historical average. A similar deterioration of multiples was last seen in 2020 at the peak of the pandemic.



### **Deconstructing the forecasts**

### **Advanced Materials (formerly Protective Films)**

The stable margins in the protective films business in H1 (8.4% EBIT margin, unchanged vs. H1 2021) highlights the company's good pricing power in the current inflationary environment and the flexibility of its commercial, industrial, and logistics organisation. The efforts made to lower the breakeven point in previous years are now paying off (automation of production lines, workforce flexibility, premiumisation).

The fundamentals of the business remain solid despite macro headwinds (e.g. established global leadership, premium positioning, state-of-the-art production assets, low capex required in the near future, large and diversified customer base). The company reported further market share gains too. Management has reiterated its belief that the division could generate an EBIT margin of 10-12% under normal conditions.

The order backlog provides very limited visibility over the next six to eight weeks. The company reported a decrease of this backlog due to lower demand from key sectors (construction, appliances). Although the commercial momentum varies depending on the region (still okay in the US, more difficult in Europe, particularly in Germany) the lack of visibility and macro-related uncertainties prevail.

In our discussion with the company, the CFO highlighted the company's proven resilience in tough economic environments (one-quarter down during the pandemic) and mentioned that the European governments' stimulus plans could support demand in the future.

We model no sales growth and limited margin expansion in 2023 due to economic slowdown, a demanding base for comparison, and high price for polyethylene.

	2019	2020	2021	2022E	2023E	2024E	2025E
Sales	278	270	341	351	351	358	372
YOY change %	-2%	-3%	26%	3%	0%	2%	4%
EBITDA	33	28	37	38	40	42	45
% of sales	11.9%	10.3%	10.8%	10.8%	11.3%	11.8%	12%
EBIT, adj.	24	17	26	28	30	32	34
% of sales	8.5%	6.3%	7.7%	8.0%	8.5%	9.0%	9.2%

### **Fashion Technologies**

The recovery seen in the first half (sales have doubled) was driven by the rebound in the fashion market (penalised by lockdowns until the start of H2 2021), and some commercial success with key accounts. Margins also doubled thanks to the operating leverage provided by volumes and the company's ability to pass rising costs on to selling prices. The order backlog stands at record levels.

So far, management sees no particular slowdown in demand, although it takes a prudent stance on the future (limited visibility over two months). The business is exposed to retail fashion and therefore to a global economic slowdown.

We see 2022 sales matching pre-Covid levels thanks to solid pricing along with a recovery in margins thanks to higher volume. In 2023, we model no top-line growth and limited margin expansion.

	2019	2020	2021	2022E	2023E	2024E	2025E
Sales	211	132	169	202	202	208	214
YOY change %	31%	-37%	29%	23%	0%	3%	3%
EBITDA	24	11	11	20	21	22	24
% of sales	11.4%	8.4%	6.3%	10.0%	10.5%	10.8%	11%
EBIT, adj.	18	5	5	14	15	16	17
% of sales	8.3%	3.9%	2.7%	7.0%	7.5%	7.8%	8.0%

Source: Kepler Cheuvreux

### **Museum Studio (formerly Museum Services)**

The build-up continues. Chargeurs' vision of forming a global integrated player in the field of museum services is taking shape. The last acquisition was Skira, a world-renowned publisher of classical and modern art and design books (EUR15m annuals sales). By integrating subsidiaries under a common brand ("Museum Studio"), Chargeurs is developing a one-stop shop offering (creative design, editing, build, fit-out, management services, procurement, etc.) with a global reach. This stands in contrast to the current state of the industry, which basically consists of many local players with a limited range of services. The end goal is to help museums grow as brands, optimise the monetisation of their audience, and maximise their revenues.

The contribution of sizeable museum projects (renovation of the Grand Mosque, renovation of the East Wing of the National Air & Space Museum in Washington DC) will only start to be reflected in numbers in H2 2023 and beyond (revenue recognition spread over several years).

During this period, the portion of its business linked to events (25% of division sales) is likely to remain weak and will not compensate for the lag time in the execution of the major museum contracts won in 2021 and 2022.

We model double-digit growth going forward thanks to: 1) the execution of major contracts won in 2021 and 2022 and contributing as of H2 2023 (revenue recognised upon completion); and 2) the realisation of commercial synergies between newly integrated entities. The execution of large-scale projects will have a positive impact on profitability as of next year.

	2019	2020	2021	2022E	2023E	2024E	2025E
Sales	14	41	50	81	105	131	157
YOY change %	NA	196%	23%	63%	29%	25%	20%
EBITDA	5	5	9	10	14	18	22
% of sales	33%	12%	17%	12%	13%	14%	14%
EBIT, adj.	3	2	5	6	9	13	17
% of sales	20%	5%	10%	7.0%	8.5%	10%	10.5%

### **Luxury Fibers (formerly Luxury Materials)**

According to management, the expansion of the Nativa label has the potential to change the economic profile of this business unit, enabling it to go from a virtually zero-growth/low-margin business to a c. 10% margin business. Today, about 10% of the wool volume supplied is Nativa-denominated and it is growing rapidly.

As a reminder, the Nativa proprietary label guarantees the full traceability of the wool "from the sheep to the shop", ensuring that the wool supplied to brands comes from regenerative agriculture. This is made possible by the long-term relationships that Chargeurs has formed with the sheep farmers in the southern hemisphere (Oceania, South Africa, Uruguay, Argentina).



Chargeurs is marketing the solution directly to luxury fashion brands (e.g. Stella McCartney and Vivienne Westwood are customers). By offering this service to brands (traceability, sustainability), Chargeurs breaks away from the traditional wool trading business (i.e. purchasing wool from farmers/combing mills and selling it to spinners at a low margin).

As we wait for tangible commercial signings for Nativa, we foresee a gradual return to pre-Covid revenue and profit (c. EUR100m in sales, c. 3% operating margin).

	2019	2020	2021	2022E	2023E	2024E	2025E
Sales	100	65	86	103	103	106	110
YOY change %	2%	-36%	33%	20%	0%	2%	4%
EBITDA	3	-2	1	2	3	3	3
% of sales	2.8%	-3.4%	1.4%	2.0%	2.5%	3.0%	3.0%
EBIT, adj.	3	-2	1	2	2	3	3
% of sales	2.7%	-3.6%	1.2%	1.8%	2.3%	2.6%	2.8%

Source: Kepler Cheuvreux

### Personal care (formerly Healthcare Solutions)

Chargeurs intends to grow in the field of high-end premium personal care and wellness, based on a niche approach and a selective distribution strategy (pharmacies and travel retail). It plans to reach this goal through bolt-on acquisitions of upscale brands. So far, Chargeurs has made the modest acquisition of high-end hair accessory brand Fournival Altesse in 2021 (low-singledigit million revenues on an annual basis).

The business of protective face masks is deflating quickly as health conditions improve (virtually no revenue in O2). Chargeurs makes no secret of the fact that it has no big ambitions in this business, suggesting that it will not make any additional commercial efforts or invest further in this activity going forward. The business is correlated to restocking by a limited number of customers based on how the health situation unfolds.

That is what drives a new cut in estimates for the Personal Care unit (from EUR40m to EUR10m in 2022 and from EUR30m to EUR5m in 2023).

	2019	2020	2021	2022E	2023E	2024E	2025E
Sales	0	304	95	10	5	6	7
Change	NA	NA	-65%	-89%	-50%	20%	17%
EBITDA	0	65	23	2	1	1	1
% of sales	NA	21.5%	23.8%	20%	20%	20%	20%
EBIT, adj.	0	65	23	1	1	1	1
% of sales	NA	22%	24%	15%	20%	20%	20%

### **Swaine**

Chargeurs entered the luxury accessory market in 2021 through the takeover of Swaine, an iconic brand in the British ultra-luxury space that manufactures leather goods, as well as umbrellas and hats.

Chargeurs is currently repositioning the brand (new logo, new boutique in Mayfair, new target customer profile, etc.). It will leverage the manufacturing assets of Cambridge Satchel's<sup>1</sup> production assets and skills to boost Swaine's growth and profitability.

Despite being a well-known and reputable brand in the UK, the brand only generates very limited revenues at the moment, somewhere in the low-single-digit million range due to the absence of a genuine expansion policy carried out by previous owners and very limited distribution outside London.

keplercheuvreux.com

<sup>&</sup>lt;sup>1</sup> Acquired by Chargeurs in August 2022. Cambridge Satchel is a designer, manufacturer, and distributor of premium leather bags and satchels. The company employs 60 people and operates a manufacturing facility based in Cambridge.

Equity Research from Kepler Cheuvreux

The contribution of Swaine to group revenue will be marginal in the short term (a few millions). We think the investments made in the brand and distribution could boost sales into the double-digit million range by 2025, along with the high margins typically found in the luxury business. We are not making any financial projections for the time being.

### **Company description**

Chargeurs is an industrial conglomerate that has established world-leading positions in niche markets (protective films, interlinings, premium wool trading, services to museums). In 2020, Chargeurs succesfully created Healthcare Solutions (CHS) to meet the booming demand for masks during the pandemic.

### Management

Michaël Fribourg, CEO Olivier Buquen, CFO Gustave Gauquelin, COO


#### **Key shareholders**

Free float	73.00%
Colombus Holding SAS	26.70%
Sycomore Asset Management	6.60%
Amundi	6.10%

### **Key data charts**














### **SWOT** analysis

### **Strengths**

- Dominating position in niche markets (EUR0.5-1.0bn market size)
- Differentiated offering (premium products, high quality services)
- Management (long term vision, entrepreneurial approach)
- Self-financing ability

### Weaknesses

Sensitive to economic downturns (construction, apparel sector)

### **Opportunities**

- Fast-growing museum services market
- Development of a platform around healthcare/beauty/hygiene/wellness
- M&A opportunities could arise as the crisis eases
- Growing demand for eco-friendly and sophisticated products

### **Threats**

- Risks linked to the integration of newly-acquired companies
- Deep economic recession.
- Volatility of raw material price (polyester, polyamides)
- Intensification of the competitive landscape

Valuation table							Ma	arket data as	of: 27 Septe	mber 2022
FY to 31/12 (EUR)	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22E	12/23E	12/24E
Per share data (EUR)										
EPS adjusted	0.79	1.09	1.09	1.14	0.66	1.79	1.32	0.94	1.02	1.32
% Change		37.8%	-0.1%	4.7%	-42.5%	173.7%	-26.5%	-28.8%	8.1%	29.6%
EPS adjusted and fully diluted	0.79	1.09	1.09	1.14	0.66	1.79	1.31	0.93	1.01	1.30
% Change		37.8%	-0.1%	4.7%	-42.4%	173.7%	-27.2%	-28.8%	8.1%	29.6%
EPS reported	0.79	1.09	1.09	1.14	0.66	1.79	1.32	0.94	1.02	1.32
% Change		37.8%	-0.1%	4.7%	-42.5%	173.7%	-26.5%	-28.8%	8.1%	29.6%
EPS Consensus								1.23	1.59	2.02
Cash flow per share	1.65	1.35	1.33	0.62	1.11	3.19	2.77	1.54	1.83	2.11
Book value per share	11.18	9.90	9.93	10.16	10.16	10.21	11.34	10.95	11.18	11.65
DPS	0.30	0.55	0.60	0.67	0.40	1.32	1.24	0.70	0.76	0.99
Number of shares, YE (m)	19.6	23.0	23.2	23.3	22.9	22.9	23.6	23.6	23.6	23.6
Nbr of shares, fully diluted, YE (m)	19.6	23.0	23.2	23.3	22.9	22.9	23.6	23.6	23.6	23.6
Share price										
Latest price / year end	9.0	16.0	25.3	16.8	17.3	17.6	26.1	11.4	11.4	11.4
52 week high	9.1	16.1	26.7	28.5	21.7	20.0	28.9	26.1		
52 week low	8.8	7.5	15.9	15.0	14.9	8.7	17.3	11.4		
Average price (Year)	8.9	11.3	22.8	23.1	17.5	15.8	23.1	11.4	11.4	11.4
Enterprise value (EURm)										
Market capitalisation	175.1	259.3	527.6	539.0	401.2	361.7	544.5	268.9	268.9	268.9
Net financial debt	-23.3	-3.2	-8.9	92.2	122.4	147.0	123.5	148.4	144.0	135.2
Pension provisions	14.6	16.7	16.4	17.4	18.3	16.8	14.6	14.6	14.6	14.6
IFRS 16 debt	0.0	0.0	0.0	0.0	26.4	38.1	31.9	31.9	31.9	31.9
Market value of minorities	3.1	0.0	0.0	0.0	0.0	0.8	-0.6	-0.6	-0.6	-0.6
MV of equity affiliates (net of tax)	-18.1	-14.9	-11.7	-13.1	-12.6	-7.0	-7.9	-7.9	-7.9	-7.9
Others	0.0	0.0	0.0	0.0	0.0	-20.3	-6.7	0.0	0.0	0.0
Enterprise value	151.4	257.9	523.4	635.5	555.7	537.1	699.3	455.3	450.9	442.1
Valuation										
P/E adjusted	11.3	10.4	20.9	20.3	26.7	8.8	17.5	12.1	11.2	8.7
P/E adjusted and fully diluted	11.3	10.4	21.0	20.3	26.7	8.8	17.7	12.3	11.3	8.8
P/E consensus								9.3	7.2	5.6
P/BV	0.8	1.1	2.3	2.3	1.7	1.6	2.0	1.0	1.0	1.0
P/CF	5.4	8.3	17.2	37.4	15.8	5.0	8.3	7.4	6.2	5.4
Dividend yield (%)	3.4%	4.9%	2.6%	2.9%	2.3%	8.3%	5.4%	6.2%	6.7%	8.7%
FCF yield (%)	10.5%	7.8%	3.2%	-1.8%	0.0%	16.1%	9.6%	8.8%	11.2%	13.4%
ROE (%)		11.2%	11.0%	11.4%	6.4%	17.6%	12.4%	8.4%	9.2%	11.5%
ROIC (%)		17.7%	19.5%	16.4%	9.5%	18.9%	12.7%	9.4%	10.4%	12.1%
EV/Sales	0.30	0.51	0.98	1.11	0.89	0.65	0.95	0.61	0.59	0.55
EV/EBITDA adj.	3.8	5.3	9.6	10.6	9.3	5.2	9.5	6.9	6.3	5.5
EV/EBIT adj.	4.9	6.6	11.8	13.0	13.4	6.8	13.8	10.5	9.1	7.6
EV/NOPAT	3.5	7.8	13.6	15.5	17.7	7.5	14.0	12.3	10.7	9.0
EV/IC	0.9	1.3	2.7	2.1	1.5	1.3	1.8	1.1	1.1	1.1
ROIC/WACC		2.0	2.3	1.9	1.1	2.2	1.5	1.1	1.2	1.4
EV/IC over ROIC/WACC		0.6	1.2	1.1	1.4	0.6	1.2	1.0	0.9	0.8

### **Income statement**

FY to 31/12 (EUR)	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22E	12/23E	12/24E
Sales	498.7	506.4	533.0	573.3	626.1	822.0	736.6	747.8	766.6	809.0
Gross profit	120.5	130.0	141.6	154.3	166.9	219.0	186.3	192.9	201.5	216.7
EBITDA reported	40.3	48.8	54.6	59.8	59.9	102.4	73.8	65.7	71.8	81.1
EBITDA adjusted	40.3	48.8	54.6	59.8	59.9	102.4	73.8	65.7	71.8	81.1
Depreciation and amortisation	-9.7	-9.9	-10.2	-11.7	-21.1	-28.4	-28.1	-25.2	-25.4	-26.3
Goodwill impairment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other financial result and associates	-6.6	-5.0	-5.9	-5.9	-7.0	-18.2	-4.0	-4.0	-4.0	-4.0
EBIT reported	24.0	33.9	38.5	42.2	31.8	55.8	41.7	36.5	42.5	50.8
EBIT adjusted	30.6	38.9	44.4	49.0	41.4	79.3	50.7	43.5	49.5	57.8
Net financial items	-3.0	-0.5	-7.5	-8.8	-9.8	-4.9	-8.6	-10.8	-14.7	-14.7
Associates	-10.7	-2.0	-0.8	0.1	-0.4	-1.7	0.7	2.0	2.0	2.0
Others	-2.3	-1.5	-1.0	-1.8	-1.7	-4.6	-2.0	-2.0	-2.0	-2.0
Earnings before tax	8.0	29.9	29.2	31.7	19.9	44.6	31.8	25.7	27.8	36.2
Tax	7.5	-4.9	-4.0	-5.1	-4.9	-4.3	-0.5	-3.6	-3.9	-5.1
Net profit from continuing op.	15.5	25.0	25.2	26.6	15.0	40.3	31.3	22.2	24.0	31.0
Net profit from disc. activities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit before minorities	15.5	25.0	25.2	26.6	15.0	40.3	31.3	22.2	24.0	31.0
Minorities	0.0	0.0	0.0	0.0	0.0	0.7	-0.2	0.0	0.0	0.0
Net profit reported	15.5	25.0	25.2	26.6	15.0	41.0	31.1	22.2	24.0	31.0
Adjustments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit adjusted	15.5	25.0	25.2	26.6	15.0	41.0	31.1	22.2	24.0	31.0
Sales % Change		1.5%	5.3%	7.6%	9.2%	31.3%	-10.4%	1.5%	2.5%	5.5%
EBITDA reported % Change		21.1%	11.9%	9.5%	0.2%	71.0%	-27.9%	-11.0%	9.4%	12.9%
EBITDA adjusted % Change		21.1%	11.9%	9.5%	0.2%	71.0%	-27.9%	-11.0%	9.4%	12.9%
EBIT reported % Change		41.3%	13.6%	9.6%	-24.6%	75.5%	-25.3%	-12.5%	16.5%	19.6%
EBIT adjusted % Change		27.1%	14.1%	10.4%	-15.5%	91.5%	-36.1%	-14.3%	13.8%	16.8%
Earnings before tax % Change		273.8%	-2.3%	8.6%	-37.2%	124.1%	-28.7%	-19.2%	8.2%	29.9%
Net profit from cont. op. % Change		61.3%	0.8%	5.6%	-43.6%	168.7%	-22.3%	-29.2%	8.1%	29.6%
Net profit reported % Change		61.3%	0.8%	5.6%	-43.6%	173.3%	-24.1%	-28.8%	8.1%	29.6%
Net profit adjusted % Change		61.3%	0.8%	5.6%	-43.6%	173.3%	-24.1%	-28.8%	8.1%	29.6%
Gross profit margin (%)	24.2%	25.7%	26.6%	26.9%	26.7%	26.6%	25.3%	25.8%	26.3%	26.8%
EBITDA margin (%)	8.1%	9.6%	10.2%	10.4%	9.6%	12.5%	10.0%	8.8%	9.4%	10.0%
EBIT margin (%)	6.1%	7.7%	8.3%	8.5%	6.6%	9.6%	6.9%	5.8%	6.5%	7.1%
Net profit margin (%)	3.1%	4.9%	4.7%	4.6%	2.4%	5.0%	4.2%	3.0%	3.1%	3.8%
Tax rate (%)	40.1%	-15.4%	-13.3%	-16.1%	-24.0%	-9.3%	-1.6%	-15.0%	-15.0%	-15.0%
Payout ratio (%)	38.0%	50.5%	55.2%	58.9%	61.0%	73.6%	95.0%	75.7%	75.7%	75.7%
EPS reported (EUR)	0.79	1.09	1.09	1.14	0.66	1.79	1.32	0.94	1.02	1.32
EPS adjusted (EUR)	0.79	1.09	1.09	1.14	0.66	1.79	1.32	0.94	1.02	1.32
EPS adj and fully diluted (EUR)	0.79	1.09	1.09	1.14	0.66	1.79	1.31	0.93	1.01	1.30
DPS (EUR)	0.30	0.55	0.60	0.67	0.40	1.32	1.24	0.70	0.76	0.99
EPS reported % Change		37.8%	-0.1%	4.7%	-42.5%	173.7%	-26.5%	-28.8%	8.1%	29.6%
EPS adjusted % Change		37.8%	-0.1%	4.7%	-42.5%	173.7%	-26.5%	-28.8%	8.1%	29.6%
EPS adj and fully diluted % Change		37.8%	-0.1%	4.7%	-42.4%	173.7%	-27.2%	-28.8%	8.1%	29.6%
DPS % Change		83.3%	9.1%	11.7%	-40.3%	230.0%	-6.1%	-43.2%	8.1%	29.6%
Consensus Sales (EURm)								812.4	849.6	894.5
Consensus EBITDA (EURm)								78.4	90.9	104.9
Consensus EBIT (EURm)								47.1	52.9	64.7
Consensus EPS (EUR)								1.23	1.59	2.02



Cash flow statement							Ma	arket data as	of: 27 Septer	mber 2022
FY to 31/12 (EUR)	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22E	12/23E	12/24E
Net profit before minorities	15.5	25.0	25.2	26.6	15.0	40.3	31.3	22.2	24.0	31.0
Depreciation and amortisation	9.7	9.9	10.2	11.7	21.1	28.7	28.6	22.2	22.4	23.3
Goodwill impairment	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Change in working capital	8.0	0.8	-6.7	-22.5	-13.3	2.6	21.9	-6.1	-1.1	-2.5
Others	-0.8	-4.6	2.0	-1.4	2.6	1.4	-16.4	-2.0	-2.0	-2.0
Levered post tax CF before capex	32.4	31.1	30.7	14.4	25.4	73.0	65.4	36.3	43.2	49.8
% Change		-4.0%	-1.3%	-53.1%	76.4%	187.4%	-10.4%	-44.5%	19.0%	15.2%
Capex	-14.1	-10.9	-13.6	-24.3	-25.3	-14.9	-13.0	-12.7	-13.0	-13.8
Free cash flow	18.3	20.2	17.1	-9.9	0.1	58.1	52.4	23.6	30.2	36.0
% Change		10.4%	-15.3%	-chg	+chg	58000.0%	-9.8%	-55.0%	27.9%	19.4%
Acquisitions	0.0	-19.7	-5.5	-65.0	-9.6	-53.0	-20.4	-10.0	0.0	0.0
Divestments	1.2	-0.7	1.2	-1.0	0.2	-9.0	16.5	0.0	0.0	0.0
Dividend paid	-3.2	-11.5	-6.6	-10.8	-8.6	-5.9	-17.7	-29.2	-16.6	-18.0
Share buy back	0.0	0.0	0.0	-10.2	-9.8	-0.1	0.0	0.0	0.0	0.0
Capital increases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Others	7.0	-8.4	-0.5	-4.2	-2.6	-14.7	-7.3	-9.2	-9.2	-9.2
Change in net financial debt	-23.3	20.1	-5.7	101.1	30.3	24.6	-23.5	24.9	-4.3	-8.8
Change in cash and cash equiv.		63.8	53.3	-104.8	-16.1	115.1	10.7	80.1	4.3	8.8
Attributable FCF	18.3	20.2	17.1	-9.9	0.1	58.1	52.4	23.6	30.2	36.0
Cash flow per share (EUR)	1.65	1.35	1.33	0.62	1.11	3.19	2.77	1.54	1.83	2.11
% Change		-18.0%	-2.1%	-53.5%	80.0%	187.8%	-13.2%	-44.5%	19.0%	15.2%
FCF per share (EUR)	0.93	0.88	0.74	-0.42	0.00	2.54	2.22	1.00	1.28	1.53
% Change		-5.7%	-16.1%	-chg	+chg	58081.7%	-12.6%	-55.0%	27.9%	19.4%
Capex / Sales (%)	2.8%	2.2%	2.6%	4.2%	4.0%	1.8%	1.8%	1.7%	1.7%	1.7%
Capex / D&A (%)	145.4%	110.1%	133.3%	207.7%	119.9%	52.5%	46.3%	50.5%	51.4%	52.4%
Cash flow / Sales (%)	6.5%	6.1%	5.8%	2.5%	4.1%	8.9%	8.9%	4.9%	5.6%	6.2%
FCF / Sales (%)	3.7%	4.0%	3.2%	-1.7%	0.0%	7.1%	7.1%	3.2%	3.9%	4.5%
FCF Yield (%)	10.5%	7.8%	3.2%	-1.8%	0.0%	16.1%	9.6%	8.8%	11.2%	13.4%
Unlevered FCF Yield (%)	13.5%	9.8%	4.9%	0.1%	2.2%	13.1%	9.4%	8.4%	10.9%	12.5%

### **Balance sheet**

FY to 31/12 (EUR)	12/15	12/16	12/17	12/18	12/19	12/20	12/21	12/22E	12/23E	12/24E
Cash and cash equivalents	97.7	161.5	214.8	110.0	93.9	209.0	219.7	299.8	304.2	313.0
Inventories	101.0	105.4	107.3	128.4	126.1	139.1	150.1	173.6	177.9	187.8
Accounts receivable	118.4	123.2	128.0	96.1	102.6	126.4	119.0	137.6	141.1	148.9
Other current assets	1.1	0.5	0.4	0.7	1.4	2.9	6.2	6.2	6.2	6.2
Current assets	318.2	390.6	450.5	335.2	324.0	477.4	495.0	617.2	629.3	655.8
	== 0					101.0	440 =	4400	445.0	
Tangible assets	55.9	61.8	63.2	80.7	113.1	121.2	116.7	116.2	115.9	115.4
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Intangible assets	78.5	92.1	88.3	158.1	173.1	228.7	238.1	248.3	248.5	248.7
Financial assets	18.1	14.9	11.7	13.1	12.6	7.0	7.9	7.9	7.9	7.9
Other non-current assets	29.7	31.9	33.4	39.0	41.2	45.9	75.1	75.1	75.1	75.1
Non-current assets	182.2	200.7	196.6	290.9	340.0	402.8	437.8	447.5	447.4	447.1
Short term debt	25.3	25.2	26.6	33.1	22.8	46.5	39.4	39.4	39.4	39.4
Accounts payable	178.4	181.7	187.0	159.1	151.1	189.9	230.3	266.3	273.0	288.1
Other short term liabilities	1.8	3.7	4.1	1.4	6.0	26.7	12.9	12.9	12.9	12.9
Current liabilities	205.5	210.6	217.7	193.6	179.9	263.1	282.6	318.6	325.3	340.4
Long term debt	49.1	133.1	179.3	169.1	193.5	309.5	303.8	408.8	408.8	408.8
Pension provisions	14.6	16.7	16.4	17.4	18.3	16.8	14.6	14.6	14.6	14.6
IFRS16 Debt	0.0	0.0	0.0	0.0	26.4	38.1	31.9	31.9	31.9	31.9
Other long term provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	8.8	3.6	3.8	8.8	13.5	20.3	32.6	32.6	32.6	32.6
Non-current liabilities	72.5	153.4	199.5	195.3	251.7	384.7	382.9	487.9	487.9	487.9
Shareholders' equity	219.3	227.3	229.9	237.2	232.4	233.2	267.4	258.3	263.6	274.7
Minority interests	3.1	0.0	0.0	0.0	0.0	-0.8	-0.6	-0.6	-0.6	-0.6
Total equity	222.4	<b>227.3</b>	<b>229.9</b>	<b>237.2</b>	<b>232.4</b>	<b>232.4</b>	266.8	257.7	<b>263.0</b>	274.1
Total equity	222.4	221.3	223.3	231.2	232.4	232.4	200.0	251.1	203.0	214.1
Balance sheet total	500.4	591.3	647.1	626.1	664.0	880.2	932.3	1,064.2	1,076.2	1,102.4
% Change		18.2%	9.4%	-3.2%	6.1%	32.6%	5.9%	14.2%	1.1%	2.4%
Book value per share (EUR)	11.18	9.90	9.93	10.16	10.16	10.21	11.34	10.95	11.18	11.65
% Change		-11.4%	0.3%	2.3%	0.0%	0.5%	11.1%	-3.4%	2.1%	4.2%
Net financial debt	-23.3	-3.2	-8.9	92.2	122.4	147.0	123.5	148.4	144.0	135.2
IFRS16 Debt	0.0	0.0	0.0	0.0	26.4	38.1	31.9	31.9	31.9	31.9
Pension provisions	14.6	16.7	16.4	17.4	18.3	16.8	14.6	14.6	14.6	14.6
Others	0.0	0.0	0.0	0.0	0.0	-20.3	-6.7	0.0	0.0	0.0
Net debt	-8.7	13.5	7.5	109.6	167.1	181.6	163.3	194.9	190.5	181.7
Net fi. debt (+IFRS16) / EBITDA (x)	-0.6	-0.1	-0.2	1.5	2.5	1.8	2.1	2.7	2.4	2.1
Trade working capital	41.0	46.9	48.3	65.4	77.6	75.6	38.8	44.9	46.0	48.5
Net working capital	40.3	43.7	44.6	64.7	73.0	51.8	32.1	38.2	39.3	41.8
NWC/Sales	8.1%	8.6%	8.4%	11.3%	11.7%	6.3%	4.4%	5.1%	5.1%	5.2%
Inventories/sales	20.3%	20.8%	20.1%	22.4%	20.1%	16.9%	20.4%	23.2%	23.2%	23.2%
Invested capital	174.7	197.6	196.1	303.5	359.2	401.7	386.9	402.7	403.7	405.9
Net fin. debt / FCF (x)	-1.3	-0.2	-0.5	-9.3	1,224.0	2.5	2.4	6.3	4.8	3.8
Gearing (%)	-10.5%	-1.4%	-3.9%	38.9%	52.7%	63.3%	46.3%	57.6%	54.8%	49.3%
Goodwill / Equity (%)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

### **Research ratings and important disclosures**

The term "KEPLER CHEUVREUX" shall, unless the context otherwise requires, mean each of KEPLER CHEUVREUX and its affiliates, subsidiaries and related companies (see "Regulators" table below).

The investment recommendation(s) referred to in this report was (were) completed on 27/09/2022 16:09 (GMT) and was first disseminated on 28/09/2022 4:48 (GMT).

Unless otherwise stated, all prices are aligned with the "Market Data date" on the front page of this report.

#### Disclosure checklist - Potential conflict of interests

Company Name	ISIN	Disclosure
Chargeurs	FR0000130692	KEPLER CHEUVREUX and the issuer have agreed that KEPLER CHEUVREUX will produce and disseminate investment
		research on the said issuer as a service to the issuer

#### Organizational and administrative arrangements to avoid and prevent conflicts of interests

KEPLER CHEUVREUX promotes and disseminates independent investment research and have implemented written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business, which are available upon request. The KEPLER CHEUVREUX research analysts and other staff involved in issuing and disseminating research reports operate independently of KEPLER CHEUVREUX Investment Banking business. Information barriers and procedures are in place between the research analysts and staff involved in securities trading for the account of KEPLER CHEUVREUX or clients to ensure that price sensitive information is handled according to applicable laws and regulations.

It is Kepler Cheuvreux' policy not to disclose the rating to the issuer before publication and dissemination. Nevertheless, this document, in whole or in part, and with the exclusion of ratings, target prices and any other information that could lead to determine its valuation, may have been provided to the issuer prior to publication and dissemination, solely with the aim of verifying factual accuracy.

Please refer to www.keplercheuvreux.com for further information relating to research and conflict of interest management.

#### **Analyst disclosures**

 $The functional job title of the person(s) \ responsible for the recommendations contained in this report is \ Equity/Credit \ Research \ Analyst \ unless \ otherwise \ stated \ on the \ cover.$ 

Name of the Research Analyst(s): Baptiste de Leudeville

Regulation AC - Analyst Certification: Each Equity/Credit Research Analyst(s) listed on the front-page of this report, principally responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the equity research analyst covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each Equity/Credit Research Analyst(s) also certifies that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that equity research analyst in this research report.

Each Equity/Credit Research Analyst certifies that he is acting independently and impartially from KEPLER CHEUVREUX shareholders, directors and is not affected by any current or potential conflict of interest that may arise from any KEPLER CHEUVREUX activities.

**Analyst Compensation:** The research analyst(s) primarily responsible for the preparation of the content of the research report attest that no part of the analyst's(s') compensation was, is or will be, directly or indirectly, related to the specific recommendations expressed by the research analyst(s) in the research report. The research analyst's(s') compensation is, however, determined by the overall economic performance of KEPLER CHEUVREUX.

Registration of non-US Analysts: Unless otherwise noted, the non-US analysts listed on the front of this report are employees of KEPLER CHEUVREUX, which is a non-US affiliate and parent company of Kepler Capital Markets, Inc. a SEC registered and FINRA member broker-dealer. Equity/Credit Research Analysts employed by KEPLER CHEUVREUX, are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of Kepler Capital Markets, Inc. and may not be subject to NASD Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

### **Research ratings**

Kepler Cheuvreux rating split as of 28 September 2022		_
Rating Breakdown	A	В
Buy	59%	67%
Hold	32%	26%
Reduce	5%	0%
Not Rated/Under Review/Accept Offer	4%	7%
Total	100%	100%

Source: Kepler Cheuvreux

A: % of all research recommendations

B: % of issuers to which material services of investment firms are supplied

### 12 months rating history

The below table shows the history of recommendations and target prices changes issued by KEPLER CHEUVREUX research department (Equity and Credit) over a 12 months period.

Company Name Date Business Line Rating Target Price Closing Price

 $\label{lem:condition} \textit{Credit research does not issue target prices. Left intentionally blank.}$ 

Please refer to the following link https://research.keplercheuvreux.com/disclosure/stock/ for a full list of investment recommendations issued over the last 12 months by the author(s) and contributor(s) of this report on any financial instruments.

### **Equity research**

### Rating system

KEPLER CHEUVREUX equity research ratings and target prices are issued in absolute terms, not relative to any given benchmark. A rating on a stock is set after assessing the twelve months expected upside or downside of the stock derived from the analyst's fair value (target price) and in the light of the risk profile of the company. Ratings are defined as follows:

Buy: The minimum expected upside is 10% over next 12 months (the minimum required upside could be higher in light of the company's risk profile).

Hold: The expected upside is below 10% (the expected upside could be higher in light of the company's risk profile).



Reduce: There is an expected downside.

Accept offer: In the context of a total or partial take-over bid, squeeze-out or similar share purchase proposals, the offer price is considered to be fairly valuing the shares.

Reject offer: In the context of a total or partial take-over bid, squeeze-out or similar share purchase proposals, the offered price is considered to be undervaluing the shares.

**Under review:** An event occurred with an expected significant impact on our target price and we cannot issue a recommendation before having processed that new information and/or without a new share price reference.

Not rated: The stock is not covered.

Restricted: A recommendation, target price and/or financial forecast is not disclosed further to compliance and/or other regulatory considerations.

Due to share prices volatility, ratings and target prices may occasionally and temporarily be inconsistent with the above definition.

### Valuation methodology and risks

Unless otherwise stated in this report, target prices and investment recommendations are determined based on fundamental research methodologies and relies on commonly used valuation methodologies such as Discounted Cash Flow (DCF), valuation multiples comparison with history and peers, Dividend Discount Model (DDM).

Valuation methodologies and models can be highly dependent on macroeconomic factors (such as the price of commodities, exchange rates and interest rates) as well as other external factors including taxation, regulation and geopolitical changes (such as tax policy changes, strikes or war). In addition, investors' confidence and market sentiment can affect the valuation of companies. The valuation is also based on expectations that might change rapidly and without notice, depending on developments specific to individual industries. Whichever valuation method is used there is a significant risk that the target price will not be achieved within the expected timeframe.

Unless otherwise stated, models used are proprietary. Additional information about the proprietary models used in this report is accessible on request.

KEPLER CHEUVREUX' equity research policy is to update research rating when it deems appropriate in the light of new findings, markets development and any relevant information that can impact the analyst's view and opinion.

#### Regulators

Location	Regulator	Abbreviation
KEPLER CHEUVREUX S.A - France	Autorité des Marchés Financiers	AMF
KEPLER CHEUVREUX, Sucursal en España	Comisión Nacional del Mercado de Valores	CNMV
KEPLER CHEUVREUX, Frankfurt branch	Bundesanstalt für Finanzdienstleistungsaufsicht	BaFin
KEPLER CHEUVREUX, Milan branch	Commissione Nazionale per le Società e la Borsa	CONSOB
KEPLER CHEUVREUX, Amsterdam branch	Autoriteit Financiële Markten	AFM
Kepler Capital Markets SA - Switzerland, Zurich branch	Swiss Financial Market Supervisory Authority	FINMA
Kepler Capital Markets, Inc.	Financial Industry Regulatory Authority	FINRA
KEPLER CHEUVREUX, London branch	Financial Conduct Authority	FCA
KEPLER CHEUVREUX, Vienna branch	Austrian Financial Services Authority	FMA
KEPLER CHEUVREUX, Stockholm Branch	Finansinspektionen	FI
KEPLER CHEUVREUX Oslo Branch	Finanstilsynet	NFSA
KEPLER CHEUVREUX, Bruxelles Branch	Autorité des Services et Marchés Financiers	FSMA

KEPLER CHEUVREUX is authorised and regulated by both Autorité de Contrôle Prudentiel and Autorité des Marchés Financiers.

### **Legal and disclosure information**

### Other disclosures

This product is not for distribution to retail clients.

MIFID 2 WARNING: We remind you that pursuant to MiFID 2, it is your responsibility, as a recipient of this research document, to determine whether or not your firm is impacted by the provisions of the Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments ("MiFID 2") regarding the unbundling of research and execution (the "MiFID 2 Research Rules"). For any request on the provision of research documents, please send an email to crystal.team@keplercheuvreux.com.

The information contained in this publication was obtained from various publicly available sources believed to be reliable, but has not been independently verified by KEPLER CHEUVREUX. KEPLER CHEUVREUX does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information may be available on request.

This publication is for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction.

Any opinions, projections, forecasts or estimates in this report are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of this report and are subject to change without notice. KEPLER CHEUVREUX has no obligation to update, modify or amend this publication or to otherwise notify a reader or recipient of this publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in this report were in no way affected or influenced by the issuer. The author of this publication benefits financially from the overall success of KEPLER CHEUVREUX.

The investments referred to in this publication may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in this publication shall be the sole and exclusive responsibility of the investor and KEPLER CHEUVREUX accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in this publication may not be readily liquid investments. Consequently it may be difficult to sell or realise such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in this publication may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk.

To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of this publication or its contents.

### **Country and region disclosures**

**United Kingdom**: This document is for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Articles 19(5) (Investment professionals) and 49(2) (High net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Any investment to which this document relates is available only to such persons, and other classes of person should not rely on this document.

**United States**: This communication is only intended for, and will only be distributed to, persons residing in any jurisdictions where such distribution or availability would not be contrary to local law or regulation. This communication must not be acted upon or relied on by persons in any jurisdiction other than in accordance with local law or regulation and where such person is an investment professional with the requisite sophistication to understand an investment in such securities of the type communicated and assume the risks associated therewith.

This communication is confidential and is intended solely for the addressee. It is not to be forwarded to any other person or copied without the permission of the sender. This communication is provided for information only. It is not a personal recommendation or an offer to sell or a solicitation to buy the securities mentioned. Investors should obtain independent professional advice before making an investment.

Notice to U.S. Investors: This material is not for distribution in the United States, except to "major US institutional investors" as defined in SEC Rule 15a-6 ("Rule 15a-6"). KEPLER CHEUVREUX has entered into a 15a-6 Agreement with Kepler Capital Markets, Inc. ("KCM, Inc.") which enables this report to be furnished to certain U.S. recipients in reliance on Rule 15a-6 through KCM Inc.

Each U.S. recipient of this report represents and agrees, by virtue of its acceptance thereof, that it is a "major U.S. institutional investor" (as such term is defined in Rule 15a-6) and that it understands the risks involved in executing transactions in such securities. Any U.S. recipient of this report that wishes to discuss or receive additional information regarding any security or issuer mentioned herein, or engage in any transaction to purchase or sell or solicit or offer the purchase or sale of such securities, should contact a registered representative of KCM, Inc.

KCM, Inc. is a broker-dealer registered with the Securities and Exchange Commission ("SEC") under the U.S. Securities Exchange Act of 1934, as amended, Member of the Financial Industry Regulatory Authority ("FINRA") and Member of the Securities Investor Protection Corporation ("SIPC"). Pursuant to SEC Rule 15a-6, you must contact a Registered Representative of KCM, Inc. if you are seeking to execute a transaction in the securities discussed in this report. You can reach KCM, Inc. at Tower 49, 12 East 49th Street, Floor 36, New York, NY 10017, Compliance Department (212) 710-7625; Operations Department (212) 710-7606; Trading Desk (212) 710-7602. Further information is also available at www.keplercheuvreux.com. You may obtain information about SIPC, including the SIPC brochure, by contacting SIPC directly at 202-371-8300; website: http://www.sinc.org/

KCM, Inc. is a wholly owned subsidiary of KEPLER CHEUVREUX. KEPLER CHEUVREUX, registered on the Paris Register of Companies with the number 413 064 841 (1997 B 10253), whose registered office is located at 112 avenue Kléber, 75016 Paris, is authorised and regulated by both Autorité de Contrôle Prudentiel (ACP) and Autorité des Marchés Financiers (AMF).

Nothing herein excludes or restricts any duty or liability to a customer that KCM, Inc. may have under applicable law. Investment products provided by or through KCM, Inc. are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution, may lose value and are not guaranteed by the entity that published the research as disclosed on the front page and are not guaranteed by KCM, Inc.

Investing in non-U.S. Securities may entail certain risks. The securities referred to in this report and non-U.S. issuers may not be registered under the U.S. Securities Act of 1933, as amended, and the issuer of such securities may not be subject to U.S. reporting and/or other requirements. Rule 144A securities may be offered or sold only to persons in the U.S. who are Qualified Institutional Buyers within the meaning of Rule 144A under the Securities Act. The information available about non-U.S. companies may be limited, and



non-U.S. companies are generally not subject to the same uniform auditing and reporting standards as U.S. companies. Securities of some non-U.S. companies may not be as liquid as securities of comparable U.S. companies. Securities discussed herein may be rated below investment grade and should therefore only be considered for inclusion in accounts qualified for speculative investment.

Analysts employed by KEPLER CHEUVREUX SA, a non-U.S. broker-dealer, are not required to take the FINRA analyst exam. The information contained in this report is intended solely for certain "major U.S. institutional investors" and may not be used or relied upon by any other person for any purpose. Such information is provided for informational purposes only and does not constitute a solicitation to buy or an offer to sell any securities under the Securities Act of 1933, as amended, or under any other U.S. federal or state securities laws, rules or regulations. The investment opportunities discussed in this report may be unsuitable for certain investors depending on their specific investment objectives, risk tolerance and financial position.

In jurisdictions where KCM, Inc. is not registered or licensed to trade in securities, or other financial products, transactions may be executed only in accordance with applicable law and legislation, which may vary from jurisdiction to jurisdiction and which may require that a transaction be made in accordance with applicable exemptions from registration or licensing requirements.

The information in this publication is based on sources believed to be reliable, but KCM, Inc. does not make any representation with respect to its completeness or accuracy. All opinions expressed herein reflect the author's judgment at the original time of publication, without regard to the date on which you may receive such information, and are subject to change without notice.

KCM, Inc. and/or its affiliates may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. These publications reflect the different assumptions, views and analytical methods of the analysts who prepared them. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is provided in relation to future performance.

KCM, Inc. and any company affiliated with it may, with respect to any securities discussed herein: (a) take a long or short position and buy or sell such securities; (b) act as investment and/or commercial bankers for issuers of such securities; (c) act as market makers for such securities; (d) serve on the board of any issuer of such securities; and (e) act as paid consultant or advisor to any issuer. The information contained herein may include forward-looking statements within the meaning of U.S. federal securities laws that are subject to risks and uncertainties. Factors that could cause a company's actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company's products or services, changes in foreign exchange markets, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement.

France: This publication is issued and distributed in accordance with legal or regulatory requirements relating to independent investment research, as defined under Article 36 of the EU delegated regulation n°565/2017.

**Germany**: This report must not be distributed to persons who are retail clients in the meaning of Sec. 31a para. 3 of the German Securities Trading Act (Wertpapierhandelsgesetz – "WpHG"). This report may be amended, supplemented or updated in such manner and as frequently as the author deems.

Italy: This document is issued by KEPLER CHEUVREUX Milan branch, authorised in France by the Autorité des Marchés Financiers (AMF) and the Autorité de Contrôle Prudentiel (ACP) and registered in Italy by the Commissione Nazionale per le Società e la Borsa (CONSOB) and is distributed by KEPLER CHEUVREUX. This document is for Eligible Counterparties or Professional Clients only as defined by the CONSOB Regulation 16190/2007 (art. 26 and art. 58). Other classes of persons should not rely on this document. Reports on issuers of financial instruments listed by Article 180, paragraph 1, letter a) of the Italian Consolidated Act on Financial Services (Legislative Decree No. 58 of 24/2/1998, as amended from time to time) must comply with the requirements envisaged by articles 69 to 69-novies of CONSOB Regulation 11971/1999. According to these provisions KEPLER CHEUVREUX warns on the significant interests of KEPLER CHEUVREUX in relation to the securities object of this report as well as other circumstance or relationship with the issuer of the securities object of this report (including but not limited to conflict of interest, significant shareholdings held in or by the issuer and other significant interests held by KEPLER CHEUVREUX or other entities controlling or subject to control by KEPLER CHEUVREUX in relation to the issuer which may affect the impartiality of this document). Equities discussed herein are covered on a continuous basis with regular reports at results release. Reports are released on the date shown on cover and distributed via print and email. KEPLER CHEUVREUX branch di Milano analysts is not affiliated with any professional groups or organisations. All estimates are by KEPLER CHEUVREUX unless otherwise stated.

Spain: This document is only intended for persons who are Eligible Counterparties or Professional Clients within the meaning of Article 78bis and Article 78ter of the Spanish Securities Market Act. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This report has been issued by KEPLER CHEUVREUX Sucursal en España registered in Spain by the Comisión Nacional del Mercado de Valores (CNMV) in the foreign investments firms registry and it has been distributed in Spain by it or by KEPLER CHEUVREUX authorised and regulated by both Autorité de Contrôle Prudentiel and Autorité des Marchés Financiers. There is no obligation to either register or file any report or any supplemental documentation or information with the CNMV. In accordance with the Spanish Securities Market Law (Ley del Mercado de Valores), there is no need for the CNMV to verify, authorise or carry out a compliance review of this document or related documentation, and no information needs to be provided.

**Switzerland**: This publication is intended to be distributed to professional investors in circumstances such that there is no public offer. This publication does not constitute a prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations.

Canada: The information contained herein is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. In Canada, the information contained herein is intended solely for distribution to Permitted Clients (as such term is defined in National Instrument 31-103) with whom Kepler Capital Markets, inc. deals pursuant to the international dealer exemption. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities may not be conducted through Kepler Capital Markets, inc. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein.

Other countries: Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly.

None of the material, nor its content may be altered in anyway, transmitted to, copied or distributed to any other party, in whole or in part, unless otherwise agreed with KEPLER CHEUVREUX in writing.

 $\textbf{Copyright} \ @ \ \textbf{KEPLER} \ \textbf{CHEUVREUX.} \ \textbf{All rights} \ \textbf{reserved.}$ 








### Europe



### Amsterdam

Kepler Cheuvreux Benelux Johannes Vermeerstraat 9 1071 DK Amsterdam +31 20 563 2365





+32 11 491460

Frankfurt

Kepler Cheuvreux Germany Taunusanlage 19 60325 Frankfurt

+49 69 756 960

Geneva

Kepler Cheuvreux SA Avenue Perdtemps 23, 1260 Nyon Switzerland

+41 22361 5151

### London

Kepler Cheuvreux UK 5th Floor 95 Gresham Street London EC2V 7NA

+44 20 7621 5100



Kepler Cheuvreux Espana Paseo de la Castellana, 52 28046 Madrid

+34 914 36 5100



### Milan

Kepler Cheuvreux Italia Via C. Cornaggia 10 20123 Milan

+39 02 8550 7201



### Oslo

Kepler Cheuvreux Norway Filipstad Brygge 1 Pb. 1671 Vika 0120 Oslo

+47 23 13 9080

### Paris

Kepler Cheuvreux France 112 Avenue Kleber 75016 Paris

+33 1 53 65 35 00

### Stockholm

Kepler Cheuvreux Sweden Malmskillnadsgatan 23 11157 Stockholm +46 8 723 51 00



### Vienna

Kepler Cheuvreux Austria Schottenring 16/2 1010 Vienna

+43 1 537 124 147



Kepler Cheuvreux Switzerland Stadelhoferstrasse 22 8001 Zurich

+41 43 333 66 66

### **North America**



### New York

Kepler Capital Markets, Inc. Tower 49 12 East 49th Street, Floor 36 10017 New York, NY USA

+1 212 710 7600

